Pharmaceutical supply chain in China: Current issues and implications for health system reform

Xuan Yu, Cheng Li, Yuhua Shi and Min Yu

Health Policy, 2010, vol. 97, issue 1, 8-15

Abstract: Objective This article discusses the performance and distortions of pharmaceutical market in China and provides some reflections and policy implications for currently implemented reform.Methods This study is based on literature review and publicly available data by searching electronic databases and official web pages of the Chinese government on the internet.Results China's economic transition and the incremental and piecemeal nature of health care reform have created a pharmaceutical market with a number of deficiencies, including ineffective supervision, mark-up price pattern, distortion of the price schedule, and lack of authoritative drug formulary.Conclusions We conclude that the root cause of the market and government failures is that higher-than-cost drugs preferred by all suppliers. New drug pricing mechanism is the key to the current pharmaceutical reform and should be implemented in coordination with other health system reforms.

Keywords: Health; care; reform; Pharmaceutical; market; China (search for similar items in EconPapers)
Date: 2010
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (23)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168-8510(10)00056-4
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:97:y:2010:i:1:p:8-15

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().